minocycline and blonanserin

Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. The article explores the different novel drugs that impact some of the key neurotransmitter systems currently. Phosphodiesterase 10A inhibitors and α-7 neuronal nicotinic acetylcholine receptor modulators constitute the majority. The marketing of these medications eventually may result in change about how schizophrenia is treated.

Topics: Antipsychotic Agents; Drug Approval; Excitatory Amino Acid Agents; Glycine Agents; Humans; Minocycline; Nicotinic Agonists; Phosphodiesterase Inhibitors; Piperazines; Piperidines; Schizophrenia